UBS Group Reiterates Neutral Rating for Victrex (LON:VCT)

Victrex (LON:VCT)‘s stock had its “neutral” rating restated by research analysts at UBS Group in a report issued on Monday, ThisIsMoney.Co.Uk reports.

A number of other research firms have also issued reports on VCT. Peel Hunt restated an “add” rating on shares of Victrex in a research report on Monday, May 6th. Numis Securities restated a “hold” rating and set a GBX 2,350 ($30.71) price objective (down previously from GBX 2,550 ($33.32)) on shares of Victrex in a research report on Monday, May 13th. Barclays restated an “underweight” rating and set a GBX 2,210 ($28.88) price objective (down previously from GBX 2,420 ($31.62)) on shares of Victrex in a research report on Friday, March 29th. JPMorgan Chase & Co. reduced their price objective on Victrex from GBX 2,800 ($36.59) to GBX 2,300 ($30.05) and set a “neutral” rating for the company in a research report on Tuesday, May 14th. Finally, Liberum Capital reduced their price objective on Victrex from GBX 2,700 ($35.28) to GBX 2,600 ($33.97) and set a “buy” rating for the company in a research report on Wednesday, May 15th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of GBX 2,367.27 ($30.93).

LON:VCT opened at GBX 2,178 ($28.46) on Monday. Victrex has a 12-month low of GBX 1,943 ($25.39) and a 12-month high of GBX 3,434 ($44.87). The firm has a market cap of $1.88 billion and a price-to-earnings ratio of 18.94. The firm’s 50 day moving average is GBX 2,088.22.

In other news, insider Jane Toogood acquired 500 shares of the company’s stock in a transaction dated Friday, May 31st. The shares were bought at an average price of GBX 1,972 ($25.77) per share, with a total value of £9,860 ($12,883.84). Also, insider Jakob Sigurdsson acquired 3,000 shares of the company’s stock in a transaction dated Tuesday, May 14th. The stock was purchased at an average cost of GBX 2,092 ($27.34) per share, for a total transaction of £62,760 ($82,007.06). Insiders bought a total of 4,227 shares of company stock worth $8,198,142 in the last three months.

Victrex Company Profile

Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, ortho, dental, trauma, knee, cardiovascular, and orthopedic applications. It also offers specialist solutions for medical device manufacturers.

Featured Article: What does RSI mean?

Analyst Recommendations for Victrex (LON:VCT)

Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.